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Scientific background and objectives
Worldwide, 67 million patients are affected by the neuro-
degenerative eye disease glaucoma. Glaucomatous optic
neuropathy (GON) is the second leading cause of perma-
nent vision loss. GON is a chronic degenerative process
the onset of which is not possible to monitor by currently
existing diagnostic tools. Early treatment has been reported
to be highly beneficial for well-timed treatment measures
to slow-down the disease progression [1]. As reviewed by
the authors, molecular pathomechanisms of glaucoma
demonstrate both a considerable overlap and remarkable
particularities to some other neurodegenerative disorders
such as Alzheimer’s and Parkinson’s diseases [2]. Hence,
versus controls the neuronal thread protein (NTP) demon-
strates enhanced expression levels in glaucoma, patients
with Down Syndrome, Alzheimer’s and some other neuro-
degenerative diseases indicating the axonal lesions.
However, whereas the accumulation of TAU-protein is
characteristic for Alzheimer’s disease and other tauopa-
thies, glaucoma patients do not demonstrate an increase in
the target protein versus controls [2]. A monitoring of the
pathology-specific molecular patterns is particularly valu-
able to develop reliable diagnostic approaches before the
manifest pathology. Predictive tests can specify individual
predisposition for well-timed preventive measures.
Results interpretation
Comparative “Comet Assay” analysis revealed patterns of
comets typical for glaucoma patients and some pattern
similarities with vasospastic individuals, in contrast to
controls as shown in Figure 1 [3]. Although DNA damage
in the vasospastic non-glaucomatous group is not found
to be significantly increased versus healthy controls, DNA
from vasospastic individuals showed highly group-
specific comet-patterns with the degree of damage inter-
mediate between healthy controls and glaucoma patients.
Conclusions and outlook
These findings indicate “comet assay” profiling of DNA-
damage in CL as a potentially powerful tool for the
non-invasive early/predictive molecular diagnostics of
glaucoma disease in vasospastic individuals. Further-
more, unrepaired DNA-damage in vasospastic indivi-
duals can lead to several pathologies different from
glaucomatous optic nerve degeneration. This predisposi-
tion should be thoroughly investigated and the specifi-
city of “Comet Assay”-patterns of vasospastic individuals
should be validated comparing with patterns of other
degenerative and non-degenerative pathologies. Thus,
“Comet Assay”-analysis as a suitable tool for biomarkers
has also been suggested for another neurodegenerative dis-
order – Alzheimer’s disease [4]. “Comet Assay”-analysis
reveals enhanced DNA damage in both high- and normal-
tension glaucoma [3]. Whether the level of DNA-damage
correlates with disease severity, or not remains currently
unclear. Further studies should also evaluate, whether a sig-
nificant increase in DNA damage of leukocytes of glaucoma
patients is caused by either disease specific stress factors,
such as local ischemic/reperfusion events, and/or decreased
capacity of DNA-repair machinery. There is some evidence
for both eventualities: simultaneous up-regulation of p53
(stress regulated gene) and down-regulation of XPGC
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(essential member of DNA-repair machinery) have been
demonstrated ex vivo in CL of glaucoma patients [5] and
represent potential molecular blood markers for the
disease.
Recommendations
A potential predisposition of vasospastic individuals to
related pathologies should be thoroughly examined. This
examination requires innovative strategies to cover fol-
lowing aspects:
• identification of possible similarities as well as dis-
similarities in molecular pathways between healthy
vasospastic individuals and potential related pathologies
developed later in life
• specificity for predictive diagnostics of glaucoma
pathology in predisposed vasospastic individuals should
Figure 1 Ex vivo “Comet Assay“-analysis of DNA damage in circulating leukocytes of glaucoma patients and non-glaucomatous vasospastic
individuals versus healthy controls [3]. Figures A-D give examples of images typical for A. control group, B. group of vasospastic individuals, C.
group of normal-tension glaucoma patients, and D. group of high-tension glaucoma patients. Comet-patterns typical for healthy controls (A)
show that chromosomal DNA is localised mainly to heads of comets (intact DNA). In contrast, images B, C, and D demonstrate clearly damaged
DNA (visible comet-tails and diffuse comet-heads).
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be strictly validated against several control groups
including other neuro/degenerative diseases
• selection of molecular targets should be performed
for vasospastic individuals in favour of non-invasive
(blood test) diagnostic approaches followed by persona-
lised treatment towards individual predisposition to sin-
gle pathologies.
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